Meiji Yasuda Asset Management Co Ltd. decreased its position in Celgene Co. (NASDAQ:CELG) by 52.6% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 24,650 shares of the biopharmaceutical company’s stock after selling 27,384 shares during the quarter. Meiji Yasuda Asset Management Co Ltd.’s holdings in Celgene were worth $2,325,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Bruderman Asset Management LLC bought a new stake in shares of Celgene in the 4th quarter worth $25,000. Murphy Pohlad Asset Management LLC bought a new stake in shares of Celgene in the 4th quarter worth $25,000. Archford Capital Strategies LLC grew its stake in shares of Celgene by 277.8% in the 1st quarter. Archford Capital Strategies LLC now owns 272 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 200 shares in the last quarter. Athena Capital Advisors LLC bought a new stake in shares of Celgene in the 4th quarter worth $27,000. Finally, Investors Research Corp purchased a new position in shares of Celgene in the 1st quarter worth about $28,000. Hedge funds and other institutional investors own 75.19% of the company’s stock.

A number of brokerages recently weighed in on CELG. Zacks Investment Research downgraded shares of Celgene from a “buy” rating to a “hold” rating in a report on Wednesday, April 3rd. BidaskClub downgraded shares of Celgene from a “strong-buy” rating to a “buy” rating in a report on Wednesday. ValuEngine raised shares of Celgene from a “sell” rating to a “hold” rating in a report on Saturday, March 30th. Mizuho reissued a “buy” rating and issued a $103.00 price target on shares of Celgene in a report on Thursday, May 16th. Finally, Barclays downgraded shares of Celgene from an “overweight” rating to an “equal weight” rating and set a $102.00 price target on the stock. in a report on Friday, May 3rd. Eighteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The company currently has an average rating of “Hold” and a consensus price target of $95.56.

NASDAQ CELG opened at $96.33 on Friday. The stock has a market cap of $67.94 billion, a price-to-earnings ratio of 12.66, a price-to-earnings-growth ratio of 0.46 and a beta of 1.57. Celgene Co. has a 52 week low of $58.59 and a 52 week high of $97.07. The company has a current ratio of 2.78, a quick ratio of 2.66 and a debt-to-equity ratio of 2.42.

Celgene (NASDAQ:CELG) last released its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported $2.55 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.45 by $0.10. The business had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.01 billion. Celgene had a net margin of 30.10% and a return on equity of 106.69%. The company’s revenue was up 13.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.05 earnings per share. On average, analysts anticipate that Celgene Co. will post 9.85 earnings per share for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This report was reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another site, it was copied illegally and republished in violation of United States and international copyright legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/meiji-yasuda-asset-management-co-ltd-sells-27384-shares-of-celgene-co-nasdaqcelg/3041542.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

See Also: Understanding the different types of bonds

Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Co. (NASDAQ:CELG).

Institutional Ownership by Quarter for Celgene (NASDAQ:CELG)

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.